...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Italian journal of pediatrics >Are high cumulative doses of erythropoietin neuroprotective in preterm infants? A two year follow-up report
【24h】

Are high cumulative doses of erythropoietin neuroprotective in preterm infants? A two year follow-up report

机译：高累积剂量的促红细胞生成素对早产儿具有神经保护作用吗？两年跟踪报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Preterm infants are at risk for neurodevelopmental sequelae even in absence of major cerebral lesions. The hypothesis that Human Recombinant Erythropoietin (rEpo) could improve the neurodevelopmental outcome in risk neonates has raised the highest interest in recent years. Methods A group of preterm neonates born at a gestational age?≤?30?weeks and free from major cerebral lesions or major visual impairment, were included in the study if they had a complete neurologic evaluation for at least 24?months of postmenstrual age. They were assigned to group I in the case they had been treated with rEpo or group II if untreated. The aim was to evaluate whether rEpo, given at the high cumulative doses utilized for hematologic purposes, is able to improve the neurodevelopmental outcome in preterm infants born at a gestational age?≤?30?weeks. A group of 104 preterm neonates were studied: 59 neonates?who received rEpo for 6.9?±?2.4?weeks at a median cumulative dose of 6300 UI/Kg (6337?±?2434 UI/Kg), starting at a median age of 4?days and 45 neonates?who were born in the period preceding the routine use of rEpo. The neurodevelopmental quotient at 24?month postmenstrual age was assessed utilizing the Griffiths’ Mental Developmental Scales. Results Our results failed to show any difference in the Developmental Quotient at 24?month. Bronchopulmonary dysplasia, minor intraventricular hemorrhages and blood transfusions were the clinical features significantly related to the Developmental Quotient. Conclusions Our results do not support the hypothesis that rEpo, administered with the schedule utilized for hematologic purposes, improve the neurodevelopmental outcome of preterm neonates, at least those preterm infants free from major impairments.
机译：背景技术即使没有严重的脑部病变，早产儿也有神经发育后遗症的风险。近年来，人类重组促红细胞生成素（rEpo）可以改善新生儿的神经发育结局这一假说引起了人们的最高兴趣。方法：如果一组早产儿至少在月经后24个月进行了全面的神经系统评估，则将其胎龄≤30周并没有严重脑损伤或严重视力障碍的早产新生儿纳入研究。如果他们已经接受过rEpo治疗，则被分配为I组;如果未经治疗，则被分配为II组。目的是评估以用于血液学目的的高累积剂量给予的rEpo是否能够改善胎龄≤≤30周的早产儿的神经发育结果。研究了一组104名早产儿：59名新生儿，他们的中位累积年龄为6300 UI / Kg（6337？±？2434 UI / Kg），接受rEpo持续6.9？±2.4？周。在常规使用rEpo之前的4天内出生了45例新生儿。使用格里菲思的心理发育量表评估月经后24个月的神经发育商。结果我们的结果未能显示24个月时的发育商有任何差异。支气管肺发育不良，小脑室内出血和输血是与发育商显着相关的临床特征。结论我们的结果不支持假说，即按血液学计划使用rEpo可以改善早产儿的神经发育结局，至少对那些没有重大损伤的早产儿而言。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号